Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin. 2003

Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
Department of Cell Therapy & Transplantation Medicine, University of Tokyo Hospital, Japan.

A male patient had a relapse of myelodysplastic syndrome (MDS) 2 years after BMT from a female matched unrelated donor. Conventional cytogenetics, FISH, and short-tandem repeat chimerism analysis proved a relapse of donor origin. He underwent reduced-intensity BMT after a conditioning with fludarabine and busulfan, since he had impaired renal, liver, and pulmonary functions. Chimerism analysis on day 28 after the second BMT showed mixed chimerism of the first and the second donors, which later turned to full second-donor chimerism on day 60. He developed grade II acute GVHD of the skin and cytomegalovirus reactivation, but both were improved with methylprednisolone and ganciclovir, respectively. He remains in complete remission 6 months after the second BMT. Reduced-intensity second BMT from an alternative donor appeared to be a tolerable treatment option for donor-derived leukemia/MDS after the first conventional transplantation.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
October 2008, International journal of hematology,
Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
May 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
October 2000, Zhonghua nei ke za zhi,
Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
January 1993, Bone marrow transplantation,
Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
February 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
March 1999, Lakartidningen,
Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
June 2004, Zhongguo shi yan xue ye xue za zhi,
Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
August 2012, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
March 2006, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
Yukiko Komeno, and Yoshinobu Kanda, and Koji Kandabashi, and Masahito Kawazu, and Susumu Goyama, and Masataka Takeshita, and Yasuhito Nannya, and Miyuki Niino, and Tetsuya Nakamoto, and Mineo Kurokawa, and Shiho Tsujino, and Seishi Ogawa, and Katsunori Aoki, and Shigeru Chiba, and Toru Motokura, and Hisamaru Hirai
June 2000, Journal of the Formosan Medical Association = Taiwan yi zhi,
Copied contents to your clipboard!